CTNM (Contineum Therapeutics) Moat Score: 3/10 (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CTNM Contineum Therapeutics Inc CTNM
17 GF Score
Price $15.46
! 2 Warning Signs
View Full Analysis

What is Contineum Therapeutics Moat Score?

Contineum Therapeutics CTNM -1.37% 17 Moat Score is 3 as of Aug. 01, 2026. GuruFocus rates CTNM with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 1,394 Biotechnology companies, Contineum Therapeutics ranks better than 75.61% on this metric.

Contineum Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Contineum Therapeutics has No Moat: Contineum Therapeutics Inc operates in a competitive market with limited market leadership and no significant regulatory barriers. The company lacks strong brand strength, customer loyalty, and durable cost advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Contineum Therapeutics might have No Moat - Very weak/transient advantages.

Contineum Therapeutics  (NAS:CTNM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Contineum Therapeutics Moat Score Related Terms

CTNM vs FDMT, PRME, ARVN: Moat Score Comparison

For the Biotechnology subindustry, Contineum Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Contineum Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's Moat Score falls into.


CTNM
17GF Score
Contineum Therapeutics Inc CTNM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Contineum Therapeutics (CTNM) has a Moat Score of 3 as of Aug. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Contineum Therapeutics ranks #340 out of 1394 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Contineum Therapeutics' Moat Score too high?
Contineum Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Contineum Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Contineum Therapeutics ranks #340 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Contineum Therapeutics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Contineum Therapeutics' Moat Score compare to FDMT and PRME?
According to the Biotechnology industry distribution chart, Contineum Therapeutics ranks #340 out of 1394 companies for Moat Score. This places Contineum Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Contineum Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Contineum Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Contineum Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Contineum Therapeutics stock overvalued right now?
Contineum Therapeutics (CTNM) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Contineum Therapeutics' overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Contineum Therapeutics (CTNM), the current Moat Score is 3 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Contineum Therapeutics Business Description

Address 3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
17GF Score

Get the complete analysis for CTNM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.46
Price